OncoSil Medical (ASX:OSL) completed patient recruitment for the Pancosil study in patients with non-progressive locally advanced pancreatic cancer, with a total of 20 patients enrolled in the study, according to a Friday Australian bourse filing.
The study is a phase 1/2 feasibility trial initiated by the Amsterdam University Medical Center in the Netherlands, and it is evaluating the safety and feasibility of computed tomography (CT)-guided percutaneous radionuclide therapy using the OncoSil device.
The device delivers a targeted intratumoural placement of phosphorous-32 in the treatment of locally advanced unresectable pancreatic cancer.
The primary objective is to study a novel delivery method for the OncoSil device via a CT-guided percutaneous approach, the filing said. The firm expects preliminary data from the study to be available later this year.
The company's shares were down 2% in recent Friday trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.